In Brief: FDA device oversight hearing
This article was originally published in The Gray Sheet
Executive Summary
FDA device oversight hearing: Joint hearing of the House Government Reform/National Economic Growth Subcommittee and Human Resources Subcommittee on FDA's device program has been delayed due to scheduling difficulties and is tentatively planned for the first week of August, according to subcommittee staffers. The hearing originally was slated for June 29 ("The Gray Sheet" May 22, p. 2)...
You may also be interested in...
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.
ImmunityBio Will Aim Anktiva At Large Share Of Bladder Cancer Market
Execs Richard Adcock and Patrick Soon-Shiong told Scrip the company sees an addressable US population of about 20,000 and is aiming for ease of physician adoption.